Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Juvenile Diabetes Research Foundation and Eli Lilly are joining together to create a $3 million research effort to accelerate the pace of research for drugs and therapies to cure diabetes and its complications by developing biomarkers that can measure the progress of disease and the effectiveness of therapeutics.
Subscribe to our email newsletter
The new Juvenile Diabetes Research Foundation (JDRF)-Lilly project will support research on biomarkers for pancreatic beta cell mass and function. The JDRF-Lilly Innovative and Academic Research and Development Grants in Diabetes Biomarkers will be funded by a $3 million grant from the Lilly Foundation to JDRF over three years.
Grants by the JDRF-Lilly project will be available to both academic and commercial investigators. Grant proposals will be evaluated through JDRF’s grant review process, which includes both peer scientific review and lay review committees. For academic research and development grants, JDRF will look to proactively match academic researchers with specific scientific targets.
Paul Burn, senior vice president of research, at JDRF, said: “This project can rapidly advance the pace of scientific discovery and therapeutic developments for type I diabetes patients along multiple research pathways to finding a cure. Lilly is making a tremendous contribution to science that could, in turn, significantly improve the lives and outlooks of millions.”